Bile Duct Cancer Treatment Market is segmented By Cancer Type (Intrahepatic bile duct cancer, Extrahepatic bile duct cancer, Others), By Treatment Type (Chemotherapy, Photodynamic therapy, Surgery, Radiation therapy, Others), By End-users (Hospitals, Clinics, Cancer research institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Bile Duct Cancer Treatment Market Overview
Bile Duct Cancer Treatment Market is expected to grow at a CAGR of 8.5% during the forecast period (2024-2031).
The narrow tubes (bile ducts) that carry the digestive fluid bile are where cholangiocarcinoma, a specific type of cancer, develops. The liver, gallbladder, and small intestine are all connected by bile ducts. The factors influencing the global bile duct cancer (cholangiocarcinoma) treatment market are the increasing research and development and the growing prevalence of bile duct cancer (cholangiocarcinoma).
Bile Duct Cancer Treatment Market Scope
| Metrics | Details |
| Market CAGR | 8.5% |
| Segments Covered | By Cancer Type, By Treatment Type, By End-user, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights Request Free Sample
Bile Duct Cancer Treatment Market Dynamics
The increasing research and development are expected to drive the Bile Duct Cancer Treatment Market growth in the forecast period
A group of tumors known as cholangiocarcinoma starts in the bile ducts. The liver, gallbladder, and small intestine are all connected by branched tubes called bile ducts. They transport bile, a fluid that aids in the body's digestion of dietary lipids. After eating, bile is produced in the liver and stored in the gallbladder before being expelled into the small intestine.
The location of cholangiocarcinoma concerning the liver determines its classification. The tiny bile channels within the liver are where intrahepatic cholangiocarcinoma starts. Less than 10% of all disease cases are in this, the least prevalent form/disease cases are in this, the least prevalent form. Cholangiocarcinoma typically affects adults above the age of 65. It can be difficult to adequately treat this cancer because it is frequently not found until it has already spread. Depending on the location and stage of cancer, affected people can live for a few months to several years after diagnosis. Many university hospitals, medical facilities, and other organizations worldwide conduct bile duct cancer research. Scientists learn more every year about the disease's causes, its prevention, and its improved treatment. Only clinical trials often offer novel and promising therapies.
Limitations associated with bile duct cancer (cholangiocarcinoma) treatment options are expected to hamper the Bile Duct Cancer Treatment Market growth
Chemotherapy medications target rapidly dividing cells, which is why they are effective against cancer cells. However, other cells in the body, like those in the bone marrow, which produces new blood cells, the lining of the mouth and intestines, and hair follicles, also divide swiftly. Chemotherapy has the potential to have an adverse effect on these cells. The type and dosage of medications administered, how they are administered, and the length of treatment all affect the negative effects of chemotherapy. Included among the side effects are hair fall, oral sores, appetite loss, vomiting and nauseous, diarrhea, and neuropathy, a condition when there is damage to the nerves that can cause pain, tingling, and numbness in the hands and feet, increased risk of infections due to insufficient white blood cells.
Industry Analysis
The global bile duct cancer (cholangiocarcinoma) treatment market provides an in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement scenario, pipeline analysis, pricing analysis, etc.
COVID-19 Impact Analysis on Bile Duct Cancer Treatment Industry
During times of peak COVID-19 incidence, some individual centers have reported delaying non-urgent or elective surgery. Operating room volumes at US hospitals decreased by an average of 35% from March to July 2020 and are predicted to stay below 2019 levels for the rest of the year. Although it is unclear how these delays may affect cancer progression and patient outcomes, findings from a modeling study of 94,912 patients who undergo major cancer resections each year suggest that a 3-month surgery delay across cancers in stages I to III would result in 4755 deaths attributable to the delay, and a 6-month delay would result in deaths attributable to the delay. Surgical oncologists and multidisciplinary teams are currently concentrating on prioritizing procedures. After multidisciplinary discussion, new solutions may be needed for patients individually due to the restricted access to surgical facilities during the COVID-19 pandemic.
Bile Duct Cancer Treatment Market Segmentation Analysis
The chemotherapy segment is expected to dominate the market growth in the forecast period
Cancer-curing medications are administered intravenously (IV) or orally during chemotherapy, sometimes known as "chemo." This treatment is effective for some malignancies that have spread to organs outside the bile duct since these medications enter the bloodstream and reach every part of the body. This is a systemic treatment since the medications are distributed throughout the entire body. Doctors administer chemotherapy in cycles, each followed by a rest period to allow the body to heal. Chemotherapy cycles typically last 3 to 4 weeks. Although chemotherapy is typically not advised for people in poor health, advanced age is not a barrier in and of itself to receiving chemotherapy. Gemcitabine (Gemzar) and cisplatin are the two most often used chemotherapy medicines for bile duct cancer.
Other medicines that are occasionally used include capecitabine (Xeloda), oxaliplatin (Eloxatin), and fluorouracil (5-FU). To ensure that treatment is as effective as possible while preserving the quality of life, the doctors tailor it. If surgery is not an option, chemotherapy may be the primary treatment for spreading bile duct cancer. According to research, those with bile duct cancer that cannot be surgically removed may survive longer with the combination of gemcitabine and cisplatin. On occasion, chemotherapy treats bile duct cancer symptoms, including a tumor pressing on a nerve and producing pain.
Bile Duct Cancer Treatment Market Geographical Share
The North American region is expected to hold the largest market share in the global bile duct cancer (cholangiocarcinoma) treatment market
The increasing research and development and growing prevalence of bile duct cancer is expected to drive the market growth. Over the past few years, liver and bile duct cancer incidence rates have risen alarmingly across North America. In the US, bile duct cancer strikes about 6,000 people each year. Additionally, most Americans impacted by cancer are between the ages of 70 and 75. Cholangiocarcinoma, a type of bile duct cancer, is uncommon. Each year, it is diagnosed in about 8,000 persons in the US.
Bile Duct Cancer Treatment Market Comapanies and Competitive Landscape
The global bile duct cancer (cholangiocarcinoma) treatment market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are F.Hoffmann-La Roche Ltd, ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, Incyte Corporation, Celgene Corporation, Bayer AG, and Boston Scientific Corporation.
Incyte Corporation
Overview: Incyte is a worldwide pharmaceutical firm with offices in Morges, Switzerland, and Wilmington, Delaware. The business was launched in 2002 due to the union of Delaware-based Incyte Genomics, Inc. and Palo Alto, California-based Incyte Pharmaceuticals.
Product Portfolio: Adults with bile duct cancer that has spread or cannot be removed surgically are treated with the prescription drug PEMAZYRE. Based on the tumor response and the length of the response, PEMAZYRE is approved. Studies are still being conducted to determine whether PEMAZYRE can increase survival or symptoms.
Key Development: On April 17th, 2020, Pemigatinib (PEMAZYRE, Incyte Corporation) was given accelerated approval by the Food and Drug Administration to treat people with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that has an FGFR2 fusion or another rearrangement as identified by an FDA-approved test.
